| Literature DB >> 35003987 |
Mohammed I Habadi1, Nashaat Hamza2, Tarig H Balla Abdalla3, Afnan Al-Gedeei4.
Abstract
The possibilities of coronavirus disease 2019 (COVID-19) to present with atypical manifestations have reported. Information of COVID-19 atypical signs and symptoms is still emerging globally. One of these presentations is persistent hiccups. One of the hypotheses is that COVID-19 has been linked to several neurological manifestations and effects. Some observations noticed phrenic nerve paralysis after COVID-19 infection leading to pulmonary failure. We report one case of COVID-19-positive patient where he presented with persistent hiccups. Many predisposing factors might lead to the development of hiccups in COVID-19 infection such as a history of smoking, phrenic and vagus nerve damage or irritation, high inflammatory markers, lower lobe pneumonia, ground-glass-like appearance on x-rays. We hypothesize that hiccups are the first sign of serious deterioration of patients with COVID-19 and such patients are at high risk of developing kidney injury and intubation.Entities:
Keywords: covid-19 hicupps; covid-19 presentation; hiccups; intractable hiccups; persistent hiccups
Year: 2021 PMID: 35003987 PMCID: PMC8723778 DOI: 10.7759/cureus.20158
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1Chest x-ray of the patient at presentation
Figure 2Chest x-ray of the patient on follow-up
Figure 3Chest x-ray of the patient during admission
Summary of the course during admission
COVID-19: coronavirus disease 2019; CRP: C-reactive protein; WBC: white blood cell; CXR: chest x-ray; GFR: glomerular filtration rate; ACLS: advanced cardiovascular life support; MCV: mean corpuscular volume; RDW: random distribution width; HCT: hematocrit; PRBCs: packed red blood cells; DC: discontinued; Echo: echocardiogram; GS: general surgery; ACC: active care continues; PCV: packed cell volume; UOP: urine output; Abx: antibiotic; CCRT: critical care response team
| Date | Daily progress | Procedure done | Significant lab results |
| August 15, 2020 | Patient has dyspnea and cough. Started on IV levofloxacin (750mg ) | Admitted to the COVID-19 isolation room | Bilateral infiltrates in CXR; CRP:116.56 |
| August 16, 2020 | Patient is distressed was hypoxic (SPO2 96% on room air); patient had an anaphylactic shock and ACLS protocol was applied. | Intubated and mechanically ventilated; central venous and arterial line inserted. | GFR: 57; creatinine serum: 1.27; urea serum: 31.45; CRP: 186.81; WBC: 9.79; neutrophils: 8.93; lymphocytes: 0.33 |
| September 9, 2020 | Patient is still sedated and ventilated on a ventilator with pressure control ventilation undigested parameters of hypercapnia and hypoxia | New left arterial line inserted; removal of the old femoral line; PRBCs transfused | Hemoglobin: 8.3; MCV: 83; RDW: 15; Hct: 24.4; platelet count: 106 |
| September 10, 2020 | Patient is still sedated and ventilated on a ventilator with pressure control ventilation undigested parameters of hypercapnia and hypoxia | On high FiO2 requirements with nitric oxide inhalation 10ppm; off vasopressors | |
| September 11, 2020 | DC glycopyrrolate; resume heparin | Planned for ECHO next day | |
| September 12, 2020 | Patient on full vent support; decreased the inspiratory pressure to reduce the leak through the right-sided pneumothorax | Right chest tube has been inserted by the GS team | ECHO: technically difficult study, poor echogenicity, limited echo views; overall normal left ventricle size, global and systolic function; mild concentric LV hypertrophy; normal right ventricle size and systolic function; no pericardial effusion; CXR: right chest wall surgical emphysema and rim pneumothorax |
| September 13, 2020 | Chest drain is to be reviewed with the surgery team | Start on sildenafil; DC thiamine, ACC | |
| September 14, 2020 | Patient sedated with propofol, fentanyl; still PCV; oliguria | Norepinephrine started; sildenafil stopped; IV Lasix started | |
| September 15, 2020 | Patient is still sedated and ventilated with severe hypoxia and hypercapnia; no fever; UOP is anuric | On a small dose of norepinephrine; Lasix is running and not effective; antibiotic changed from ceftazidime to tazocin | |
| September 16, 2020 | Wean no | Double NaHCO3 dose; adjust ABx dose; enema Movicol was added | |
| September 17, 2020 | Still PCV; still CRRT on vasopressor | Off sedation but still not awake; Bactrim added | |
| September 18, 2020 | Patient is still sedated and ventilated with severe hypoxia and hypercapnia; no fever; anuric | Antibiotics modified | |
| September 19, 2020 | Patient is still on a small dose of norepinephrine; off sedation; still on pressure control ventilation with high FiO2 and respiratory acidosis; still on nitric oxide; right intercostals tube in situ | New COVID-19 assay is negative | |
| September 20, 2020 | Patient in shock | Started on IV pressors; resumed CRRT | |
| September 21, 2020 | Patient developed a severe respiratory failure and cardiac arrest in form of Brady-asystole: this has progressed despite aggressive resuscitation and deceased | Asystole on ECG |
Figure 4Chest x-ray of the patient during admission